Brain amyloidosis ascertainment from cognitive, imaging, and peripheral blood protein measures

Neurology

Volumn 84, Issue 7, 2015, Pages 729-737

  Apostolova, Liana G ^a   Hwang, Kristy S ^a   Avila, David ^a   Elashoff, David ^a   Kohannim, Omid ^a   Teng, Edmond ^a,c   Sokolow, Sophie ^a   Jack, Clifford R ^c   Jagust, William J ^d   Shaw, Leslie ^e   Trojanowski, John Q ^e   Weiner, Michael W ^f,g   Thompson, Paul M ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c MAYO CLINIC   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; APOENZYME; BRAIN DERIVED NEUROTROPHIC FACTOR; CLUSTERIN; INTERLEUKIN 13; INTERLEUKIN 6 RECEPTOR; PITTSBURGH COMPOUND B; TUMOR NECROSIS FACTOR ALPHA; 2-(4'-(METHYLAMINO)PHENYL)-6-HYDROXYBENZOTHIAZOLE; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); ANILINE DERIVATIVE; BIOLOGICAL MARKER; PEPTIDE FRAGMENT; THIAZOLE DERIVATIVE;

ADULT; AMYLOIDOSIS; AREA UNDER THE CURVE; ARTICLE; ASSESSMENT OF HUMANS; AUDITORY VERBAL LEARNING TEST; BRAIN AMYLOIDOSIS; BRAIN DISEASE; CEREBROSPINAL FLUID; COGNITION; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE COURSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TRAILS B; AGED; ALGORITHM; ALZHEIMER DISEASE; AUTOMATED PATTERN RECOGNITION; BLOOD; BRAIN; COHORT ANALYSIS; EVALUATION STUDY; FACTUAL DATABASE; GENETICS; NEUROPSYCHOLOGICAL TEST; PATHOLOGY; PSYCHOLOGY;

AGED; ALGORITHMS; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOIDOSIS; ANILINE COMPOUNDS; BIOLOGICAL MARKERS; BRAIN; COGNITION; COHORT STUDIES; DATABASES, FACTUAL; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MILD COGNITIVE IMPAIRMENT; NEUROPSYCHOLOGICAL TESTS; PATTERN RECOGNITION, AUTOMATED; PEPTIDE FRAGMENTS; POSITRON-EMISSION TOMOGRAPHY; SENSITIVITY AND SPECIFICITY; THIAZOLES;

EID: 84923217304     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000001231     Document Type: Article

References (39)

1. Johnson KA, Minoshima S, Bohnen NI, et al. Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association. Alzheimers Dement 2013;9:e1-e16.
2. Weigand SD, Vemuri P, Wiste HJ, et al. Transforming cerebrospinal fluid Ab42 measures into calculated Pittsburgh Compound B units of brain Ab amyloid. Alzheimers Dement 2011;7:133-141.
3. Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 2009;65: 403-413.
4. Jack CR Jr, Wiste HJ, Vemuri P, et al. Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Brain 2010;133:3336-3348.
5. Petersen RC, Aisen PS, Beckett LA, et al. Alzheimer's disease neuroimaging initiative (ADNI): clinical characterization. Neurology 2010;74:201-209.
6. Folstein MF, Folstein SE, McHugh PR. Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12: 189-198.
7. Kelland DZ, Lewis R, Gurevitch D. Evaluation of the repeatable cognitive-perceptual-motor battery: reliability, validity and sensitivity to diazepam. J Clin Exp Neuropsychol 1992;14:65. Abstract.
8. Rey A. L'examen Clinique en Psychologie. Paris: Presses Universitaires de France; 1964.
9. Doecke JD, Laws SM, Faux NG, et al. Blood-based protein biomarkers for diagnosis of Alzheimer disease. Arch Neurol 2012;69:1318-1325.
10. Soares HD, Potter WZ, Pickering E, et al. Plasma biomarkers associated with the apolipoprotein E genotype and Alzheimer disease. Arch Neurol 2012;69:1310-1317.
11. Ringman JM, Elashoff D, Geschwind DH, et al. Plasma signaling proteins in persons at genetic risk for Alzheimer disease: influence of APOE genotype. Arch Neurol 2012; 69:757-764.
12. Johnstone D, Milward EA, Berretta R, Moscato P. Multivariate protein signatures of pre-clinical Alzheimer's disease in the Alzheimer's Disease Neuroimaging Initiative (ADNI) plasma proteome dataset. PLoS One 2012;7: e34341.
13. Diniz BS, Teixeira AL. Brain-derived neurotrophic factor and Alzheimer's disease: physiopathology and beyond. Neuromolecular Med 2011;13:217-222.
14. O'Bryant SE, Hobson VL, Hall JR, et al. Serum brainderived neurotrophic factor levels are specifically associated with memory performance among Alzheimer's disease cases. Dement Geriatr Cogn Disord 2011;31: 31-36.
15. Angelucci F, Spalletta G, di Iulio F, et al. Alzheimer's disease (AD) and mild cognitive impairment (MCI) patients are characterized by increased BDNF serum levels. Curr Alzheimer Res 2010;7:15-20.
16. Holmes C, Cunningham C, Zotova E, et al. Systemic inflammation and disease progression in Alzheimer disease. Neurology 2009;73:768-774.
17. Kim SM, Song J, Kim S, et al. Identification of peripheral inflammatory markers between normal control and Alzheimer's disease. BMC Neurol 2011;11:51.
18. Rocha de Paula M, Gomez Ravetti M, Berretta R, Moscato P. Differences in abundances of cell-signalling proteins in blood reveal novel biomarkers for early detection of clinical Alzheimer's disease. PLoS One 2011;6: e17481.
19. Swardfager W, Lanctot K, Rothenburg L, Wong A, Cappell J, Herrmann N. A meta-analysis of cytokines in Alzheimer's disease. Biol Psychiatry 2010;68:930-941.
20. Helmy AA, Naseer MM, Shafie SE, Nada MA. Role of interleukin 6 and alpha-globulins in differentiating Alzheimer and vascular dementias. Neurodegener Dis 2012; 9:81-86.
21. Walker DG, Dalsing-Hernandez JE, Campbell NA, Lue LF. Decreased expression of CD200 and CD200 receptor in Alzheimer's disease: a potential mechanism leading to chronic inflammation. Exp Neurol 2009;215: 5-19.
22. Szczepanik AM, Funes S, Petko W, Ringheim GE. IL-4, IL-10 and IL-13 modulate A beta(1-42)-induced cytokine and chemokine production in primary murine microglia and a human monocyte cell line. J Neuroimmunol 2001; 113:49-62.
23. Thambisetty M, Simmons A, Velayudhan L, et al. Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. Arch Gen Psychiatry 2010;67:739-748.
24. Schrijvers EM, Koudstaal PJ, Hofman A, Breteler MM. Plasma clusterin and the risk of Alzheimer disease. JAMA 2011;305:1322-1326.
25. Baig S, Palmer LE, Owen MJ, Williams J, Kehoe PG, Love S. Clusterin mRNA and protein in Alzheimer's disease. J Alzheimers Dis 2012;28:337-344.
26. Guerreiro RJ, Gustafson DR, Hardy J. The genetic architecture of Alzheimer's disease: beyond APP, PSENs and APOE. Neurobiol Aging 2012;33:437-456.
27. Apostolova LG, Dinov ID, Dutton RA, et al. 3D comparison of hippocampal atrophy in amnestic mild cognitive impairment and Alzheimer's disease. Brain 2006;129: 2867-2873.
28. Apostolova LG, Dutton RA, Dinov ID, et al. Conversion of mild cognitive impairment to Alzheimer disease predicted by hippocampal atrophy maps. Arch Neurol 2006;63:693-699.
29. Apostolova LG, Mosconi L, Thompson PM, et al. Subregional hippocampal atrophy predicts Alzheimer's dementia in the cognitively normal. Neurobiol Aging 2010;31: 1077-1088.
30. Apostolova LG, Thompson PM, Green AE, et al. 3D comparison of low, intermediate, and advanced hippocampal atrophy in MCI. Hum Brain Mapp 2010;31:786-797.
31. Mazziotta J, Toga A, Evans A, et al. A probabilistic atlas and reference system for the human brain: International Consortium for Brain Mapping (ICBM). Philos Trans R Soc Lond B Biol Sci 2001;356:1293-1322.
32. Collins DL, Neelin P, Peters TM, Evans AC. Automatic 3D intersubject registration of MR volumetric data in standardized Talairach space. J Comput Assist Tomogr 1994;18:192-205.
33. Freund Y, Schapire R. A decision-theoretic generalization of online learning and an application to boosting. J Comp Sys Sci 1997;55:119-139.
34. Morra JH, Tu Z, Apostolova LG, Green AE, Toga AW, Thompson PM. Automatic subcortical segmentation using a contextual model. Med Image Comput Comput Assist Interv 2008;11:194-201.
35. Morra JH, Tu Z, Apostolova LG, et al. Validation of a fully automated 3D hippocampal segmentation method using subjects with Alzheimer's disease, mild cognitive impairment, and elderly controls. Neuroimage 2008;43: 59-68.
36. Morra JH, Tu Z, Apostolova LG, et al. Automated mapping of hippocampal atrophy in 1-year repeat MRI data from 490 subjects with Alzheimer's disease, mild cognitive impairment, and elderly controls. Neuroimage 2009;45: S3-S15.
37. Apostolova LG, Morra JH, Green AE, et al. Automated 3D mapping of baseline and 12-month associations between three verbal memory measures and hippocampal atrophy in 490 ADNI subjects. Neuroimage 2010;51:488-499.
38. Ikonomovic MD, Klunk WE, Abrahamson EE, et al. Postmortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain 2008;131: 1630-1645.
39. Jicha GA, Parisi JE, Dickson DW, et al. Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia. Arch Neurol 2006;63:674-681.